Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

AstraZeneca
Moodys
Merck
Medtronic
Mallinckrodt
Johnson and Johnson

Last Updated: December 6, 2019

DrugPatentWatch Database Preview

Litigation Details for Cephalon, Inc. v. Apotex Corp (D. Del. 2010)

See Plans and Pricing

« Back to Dashboard

Cephalon, Inc. v. Apotex Corp (D. Del. 2010)

Docket   Start Trial Date Filed 2010-12-14
Court District Court, D. Delaware Date Terminated 2013-03-30
Cause 28:1338 Patent Infringement Assigned To Gregory Moneta Sleet
Jury Demand Defendant Referred To
Parties APOTEX CORP.; APOTEX INC.; APOTEX, INC.; CEPHALON FRANCE; CEPHALON, INC.; TEVA SANTE SAS
Patents 7,132,570; 7,297,346
Attorneys Alan Richard Silverstein; Alissa K. Lipton; Amy Lane Hurwitz; Barbara R. Rudolph; Charles B. Paradis; Charles E. Lipsey; Christopher Y. Chan; Corinne Miller LaGosh; Craig M. Kuchii; Jeffrey B. Bove; Jessica R. Price; Jill K. MacAlpine; John Anderson Camp; John C. Englander; Lawrence L. Ilag; Mark J. Feldstein; Martin S. Masar , III; Martin T. LeFevour; Mary W. Bourke; Matthew Scott Nelles; Nella M. Bloom; Robert A. Pollock; Robert Breisblatt; William J. Burnett
Firms Bloom & Bloom, LLC; Flaster Greenburg, P.C.; Katten Muchin Rosenman LLP; Womble Bond Dickinson (US) LLP
Link to Docket External link to docket
Small Molecule Drugs cited in Cephalon, Inc. v. Apotex Corp
The small molecule drugs covered by the patents cited in this case are   Start Trial and   Start Trial .

Details for Cephalon, Inc. v. Apotex Corp (D. Del. 2010)

Date Filed Document No. Description Snippet Link To Document
2011-07-07 106 terms for U.S. Patent Nos. RE37,516 and o /-, C 1 r,UNl“rED sT"/§TES TR J D E 7,297,346 at this time…DISTRICT OF DELAWARE ) IN RE: ARMODAFINIL PATENT LITIGATION ) MDL Docket No. lO-md-ZZOO~GMS g ) …parties shall only address disputed terms in U.S. Patent No. 7,132,57(). The court will neither hear oral…2010 30 March 2013 1:10-cv-01078 830 Patent Defendant District Court, D. External link to document
2010-09-27 16 expiration of U.S. Patent No. R.E 37,516, U.S. Patent No. 7,132,570, and U.S. Patent No. 7,297,346. Apotex Inc… of U.S. Patent No. RE 37,516, U.S. Patent No. '7,132,570, and U.S. Patent No. 7,297,346. Except as…expiration of U.S. Patent No. RE 37,516, U.S. Patent No. 7,132,570, and U.S, Patent No. 7,297,346. Apotex Inc…expiration of U.S. Patent No. RE 37,516, U.S. Patent No. 7,132,570, and U.S. Patent No. 7,297,346. Except as …United States Patent No. 7,297,346 (“the ’346 Patent”) (collectively “the Cephaion Patents”) are invalid External link to document
2012-10-17 189 Abbreviations ’290 Patent U.S. Patent No. 4,177,290 [JTX-90] ’570 Patent U.S. Patent No. 7,132,570…001] ’855 Patent U.S. Patent No. 4,927,855 [JTX-103] ’918 Application U.S. Patent Application…SCIENCE, THE ’570 PATENT, AND THIS DISPUTE [001] This is an ANDA patent infringement case …Cephalon cited the ’855 Patent to the PTO during prosecution of the ’570 Patent. The PTO found claims…validity and the PTO’s assessment of patentability over the ’855 Patent should stand. [003] In External link to document
2012-10-17 190 Cephalon’s ’570 Patent Discloses No New Technology 6. U.S. Patent No. 7,132,570 (“the ’570 patent…;s '570 Patent Discloses No New Technology 6. U.S. Patent No. 7,132,570 ("the &… articles, 11 patents, and two pending patent applications. Tr. at …INTRODUCTION The ’570 patent-in-suit is one of a series of patents Cephalon has used to unlawfully…called “modafinil” and obtained U.S. Patent No. 4,177,290 (“the ’290 patent”) to cover it. Tr. at 84:21-25 External link to document
2012-11-07 194 Cephalon’s ’570 Patent Discloses No New Technology 6. U.S. Patent No. 7,132,570 (“the ’570 patent…’570 patent of yield data from the ’855 patent was purposeful. The inventors of the ’570 patent believed… articles, 11 patents, and two pending patent applications. Tr. at …INTRODUCTION The ’570 patent-in-suit is one of a series of patents Cephalon has used to unlawfully…called “modafinil” and obtained U.S. Patent No. 4,177,290 (“the ’290 patent”) to cover it. Tr. at 84:21-25 External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKinsey
Express Scripts
Mallinckrodt
Boehringer Ingelheim
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.